Foxo Technologies Completes Acquisition of Vector Biosource
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy ?
Acquisition Announcement: FOXO Technologies has completed the acquisition of Vector Biosource, a provider of information, data, and biospecimens for the biotechnology and pharmaceutical industries.
Financial Details: The acquisition involved a purchase price of $500,000 in cash, 60,000 shares of Series E Preferred Stock, and warrants for $2 million in common stock, with additional shares contingent on future performance. FOXO will also invest up to $1.2 million in Vector's growth initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
